Abstract

Treatment of remifentanil-induced postoperative hyperalgesia (RIH) remains a clinical challenge because the mechanisms are not fully understood. Matrix metalloproteinase-9 (MMP-9) is a key component in neuroinflammation because of its facilitation of pro-inflammatory cytokine maturation. Therefore, inhibition of MMP-9 may represent a novel therapeutic approach to the treatment of RIH. Sprague-Dawley rats were randomly divided into three groups: Control, Incision and Remifentanil. A right plantar surgical incision was performed in Group Incision, and intraoperative remifentanil (0.04 mg/kg, 0.4 ml) was infused subcutaneously for 30 min in Group Remifentanil. The results indicated that intraoperative remifentanil induced an up-regulation and activation of MMP-9 in DRGs but not spinal cords. MMP-9 was expressed primarily in DRG neurons co-expressing mu opioid receptors (MOR), and elicited interleukin-1β (IL-1β) cleavage in DRG neurons and satellite glial cells (SGCs). Intraperitoneal injection of N-acetyl-cysteine (NAC), a broadly used safe drug, significantly attenuated RIH via suppressing the activation of MMP-9 in DRGs. NAC inhibited the cleavage of IL-1β in DRGs, which is a critical substrate of MMP-9, and markedly suppressed glial activation and neuron excitability in spinal dorsal horn induced by remifentanil. These results demonstrated that NAC can effectively alleviate RIH via powerfully inhibiting MMP-9 activation in DRGs.

Highlights

  • Remifentanil is commonly administered intravenously during general anesthesia

  • The results revealed an increase in Matrix metalloproteinase (MMP)-9 activity in the dorsal root ganglia (DRG) at 24 h and 48 h after subcutaneous remifentanil infusion during surgery in group R as compared with group I (P < 0.0001)

  • We postulate that up-regulation and activation of neuronal Matrix metalloproteinase-9 (MMP-9), and subsequent IL-1β cleavage in DRGs following intraoperative remifentanil infusion triggers glial activation and sensory neuron excitability in spinal cord dorsal horn, promoting the development of remifentanil-induced postoperative hyperalgesia (RIH)

Read more

Summary

Introduction

Remifentanil is commonly administered intravenously during general anesthesia. It has contrary pronociceptive actions and promotes postoperative hyperalgesia [1, 2]. The mechanisms of remifentanil-induced hyperalgesia (RIH) might be related to spinal N-methyl-d-aspartate receptor (NMDAR)-dependent central sensitization [3, 4]. Administration of selective chemokine (C-X-C motif) receptor 2 (CXCR2) antagonist SB225002, glycogen synthase kinase-3β (GSK-3β) inhibitor TDZD8, cyclin-dependent kinase 5 (Cdk5) inhibitor roscovitine, or alpha-7 nicotinic acetylcholine receptor (α7-nAchR) agonists PHA-543613 can attenuate RIH via regulating the expression and function of spinal NMDAR [5, 10,11,12]. A safe drug, which is effective on RIH and can be used in the clinic is not yet available

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call